Halozyme Therapeutics’ (HALO) Buy Rating Reaffirmed at HC Wainwright

Posted by Brenda Bartman on Sep 2nd, 2026

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a report issued on Wednesday, Benzinga reports. They currently have a $115.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price target would suggest a potential upside of 5.87% from the company’s current price.

Several other research analysts have also recently weighed in on HALO. Leerink Partners upgraded Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $83.00 to $110.00 in a research report on Friday, August 7th. TD Cowen upped their price objective on shares of Halozyme Therapeutics from $96.00 to $105.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. UBS Group reaffirmed a “buy” rating and issued a $90.00 price target on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Finally, Morgan Stanley dropped their target price on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. Nine equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $91.20.

View Our Latest Report on HALO

Halozyme Therapeutics Stock Up 0.8%

NASDAQ:HALO traded up $0.91 during mid-day trading on Wednesday, reaching $108.63. The company’s stock had a trading volume of 618,900 shares, compared to its average volume of 1,851,854. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. The stock has a fifty day moving average of $88.52 and a 200-day moving average of $75.13. Halozyme Therapeutics has a 1 year low of $61.22 and a 1 year high of $109.66. The firm has a market capitalization of $12.33 billion, a PE ratio of 32.45, a price-to-earnings-growth ratio of 0.43 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The firm had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. During the same quarter in the previous year, the firm earned $1.54 EPS. The company’s quarterly revenue was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Equities research analysts forecast that Halozyme Therapeutics will post 7.77 earnings per share for the current year.

Insider Buying and Selling at Halozyme Therapeutics

In other news, Director Mahesh Krishnan sold 7,304 shares of the stock in a transaction on Monday, June 29th. The stock was sold at an average price of $75.00, for a total value of $547,800.00. Following the sale, the director directly owned 14,462 shares in the company, valued at approximately $1,084,650. This trade represents a 33.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $104.18, for a total value of $2,083,600.00. Following the sale, the chief executive officer owned 767,780 shares of the company’s stock, valued at approximately $79,987,320.40. The trade was a 2.54% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 32,478 shares of company stock valued at $3,076,604 in the last 90 days. Company insiders own 2.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. California State Teachers Retirement System grew its position in Halozyme Therapeutics by 7,724.2% in the second quarter. California State Teachers Retirement System now owns 10,668,044 shares of the biopharmaceutical company’s stock worth $834,988,000 after acquiring an additional 10,531,698 shares in the last quarter. Bank of America Corp DE acquired a new position in shares of Halozyme Therapeutics during the 2nd quarter worth about $214,504,000. William Blair Investment Management LLC bought a new position in Halozyme Therapeutics during the second quarter worth $196,540,000. Norges Bank acquired a new stake in Halozyme Therapeutics in the 4th quarter worth $128,201,000. Finally, Jupiter Topco LLC bought a new position in Halozyme Therapeutics during the second quarter valued at about $105,570,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Company Profile

(Get Free Report)

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.